The Filing Desk

Ocular Therapeutix vs Tango Therapeutics

Ocular Therapeutix OCUL · Tango Therapeutics TNGX · Pharmaceuticals

Tango Therapeutics reported revenue of $62 million in fiscal 2025, 1.2 times Ocular Therapeutix's $52 million in fiscal 2025. Ocular Therapeutix's revenue fell 18.5% in its latest year, and Tango Therapeutics' grew 48.3%. Ocular Therapeutix had an operating margin of -519.8%, against -178.4% at Tango Therapeutics. Free cash flow was −$217 million at Ocular Therapeutix and −$140 million at Tango Therapeutics.

Side by side

Ocular TherapeutixTango Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$52M$62M
Revenue growth−18.5%48.3%
Revenue growth a year, last 5 years24.5%52.0%
Gross margin87.3%—
Operating margin−519.8%−178.4%
Net margin−511.9%−162.8%
Free cash flow−$217M−$140M
Free cash flow margin−417.5%−224.3%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count18.3%6.3%
Last close$6.21$25.50
P/E at the last close——
Insider trades, last 12 monthsbought $461,354, sold $2.8 millionsold $7.2 million
Piotroski F-score4 of 9—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Ocular TherapeutixTango Therapeutics
Operating margin
Percent of revenue
Ocular TherapeutixTango Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ocular TherapeutixTango Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ocular Therapeutix and Tango Therapeutics pages.